Shield Therapeutics plc

Novel approvals are likely to pick up at the US Food and Drug Administration over the next several weeks, and the agency commenced its busy string of activity with green lights for Daiichi Sankyo Co.

According to US industry body PhRMA, the average R&D cost of a bringing an FDA-approved drug to patients is around $2.6bn over the past decade, including the cost of the many medicines that do not mak

UK-based HOX Therapeutics is aiming to add therapeutic options for glioma and prostate cancer patients with its lead candidate HTL001, a small peptide drug candidate that prevents the HOX gene from bi

Here's your news in brief: After the US FDA delivered a massive wave of approvals around the Thanksgiving holiday, the first week of December appeared to be a period of calm before the upcoming year-e